CMK

CMK is a RSK2 kinase inhibitor which exhibits similar potency but less chemical stability compared with FMK.

Signaling Pathways >> MAPK/ERK Pathway >> Ribosomal S6 Kinase (RSK)

Research Areas >> Cancer

CMK inhibits the growth of Cdc5 (L158G) with IC50 of 36 nM, greater than 30 μM for wild type Cdc5. CMK exhibits a concentration-dependent first cell cycle mitotic arrest in the cdc5-as1 strain with an IC50 of 1.1 μM. CMK inhibition of Cdc5 (L158G) leads to a first cell cycle anaphase arrest and delay in anaphase spindle migration[1].

For Cdc5 kinase assays, Spc72-TAP is isolated from cell extract by pulldown with IgG sepharose or rabbit IgG coupled to M-270 epoxy dynabeads and incubated in kinase buffer (25 mM HEPES, pH 8.0, 60 mM KCl, 15 mM MnCl2, 100 μg/mL BSA, 80 nM microcystin, 1mM DTT, 100 μM 200 μCi/mL [γ-32P]ATP) in the absence or presence of 100 ng purified baculovirus expressed 6xHis-Cdc5. 32P incorporation is visualized on a Typhoon PhosphorImager, and images are processed using ImageQuant software.

[1]. Snead JL, et al. A coupled chemical-genetic and bioinformatic approach to Polo-like kinase pathway exploration. Chem Biol. 2007 Nov;14(11):1261-72.

BI-D1870 | PF-4708671 | LY-2584702 tosylate salt | BIX 02565 | AT7867 | FMK | Pluripotin | Quercitrin | A-196 | LJI308 | LJH-685 | AT13148 | Carnosol